New Study Shows Promising Results For Tests That Can Help Doctors Better Evaluate Potential Heart Attacks

   New Study Shows Promising Results For Tests That Can Help Doctors Better
                       Evaluate Potential Heart Attacks

  PR Newswire

  ABBOTT PARK, Illinois, Dec. 13, 2012

- Studies have found new diagnostic tests in development for heart conditions
are expected to help clinicians reduce time to heart attack treatment and
potentially improve the way heart attacks are diagnosed in women

ABBOTT PARK, Illinois, Dec. 13, 2012 /PRNewswire/ -- Acute chest pain is one
of the most common reasons people seek emergency care, and time is a critical
factor in diagnosing and treating people who may be having a heart attack. The
latest generation of diagnostic tests in development is expected to provide
information that will be important to patient outcomes, potentially reducing
the time to diagnosis of heart attacks by several hours. The specific
performance characteristics of several troponin tests were evaluated in a new
study published in Clinical Chemistry .(1 )

Blood tests for troponin—a protein found in the heart muscle—can detect heart
muscle injury. The study, "Determination of 19 Cardiac Troponin I and T Assay
99th Percentile Values from a Common Presumably Healthy Population," evaluated
19 cardiac troponin assays in a healthy population of men and women, and
included Abbott's high sensitive Troponin-I assay currently under development.

"The focus of this study was to emphasize that presumably healthy individuals
display different concentrations of cardiac troponin when measured by numerous
troponin assays. High sensitivity troponin assays were shown to provide the
ability to measure almost 100 percent of a healthy population, and
demonstrated an important gender difference in normal cutoff cardiac troponin
levels, with men having a higher value compared to women," wrote one of the
study authors, Fred S. Apple, Ph.D., laboratory medicine and pathology,
Hennepin County Medical Center, Minneapolis.

Recent advances have led to the development of highly sensitive troponin tests
that have the potential to lead to a faster diagnosis of heart attacks. Many
patients who visit the emergency department with a suspected heart attack
currently have to undergo troponin tests upon admission, after 6 hours, and
then 12 hours later before a definitive diagnosis is made. Highly sensitive
troponin tests can potentially detect changes in troponin in 3 hours or
less,(2) which could allow doctors to reduce the time to diagnosis and
potential treatment by several hours.

"The potential to quickly provide the correct diagnosis for patients with
chest pain using these high sensitive troponin tests may help physicians
provide the right care at the right time," said David Spindell, M.D., vice
president, Medical Affairs, Abbott. "Abbott is committed to improving the
ability of physicians to accurately assess patients presenting with chest pain
by developing more sensitive tests."

About Cardiovascular Diseases

According to the World Health Organization (WHO), approximately 17 million
people worldwide die of a heart attack or a stroke each year. By 2030, an
estimated 25 million people will die from CVDs, mainly from heart disease and
stroke. Cardiovascular diseases are projected to remain the single leading
cause of death.(3)

Globally, cardiovascular disease is the main killer of older women. Women
often show different symptoms from men, which contributes to under diagnosis
of heart disease in women.(4), (5) To learn more about women's heart health,
visit www.foryourheart.com , sponsored by Abbott.

About Abbott Diagnostics

Abbott is a global leader in in vitro diagnostics and offers a broad range of
innovative instrument systems and tests for hospitals, reference labs,
molecular labs, blood banks, physician offices and clinics. With more than
22,000 customers in more than 100 countries, Abbott's diagnostic products
offer customers automation, convenience, bedside testing, cost effectiveness
and flexibility. Abbott has helped transform the practice of medical diagnosis
from an art to a science through the company's commitment to improving patient
care and lowering costs.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals and medical
products, including nutritionals, devices and diagnostics. The company employs
approximately 91,000 people and markets its products in more than 130
countries.

Abbott's information and news releases are available on the company's Web site
at www.abbott.com .

1. Apple, et. al. Determination of 19 Cardiac Troponin I and T Assay 99th
Percentile Values from a Common Presumably Healthy Population, Clinical
Chemistry , 58:11 (2012). 2. Hamm, et. al. ESC Guidelines for the management
of acute coronary syndromes in patients presenting without persistent
ST-segment elevation The Task Force for the management of acute coronary
syndromes (ACS) in patients presenting without persistent ST-segment elevation
of the European Society of Cardiology (ESC), European Heart Journal . (2011)
32, 2999–3054. 3. Cardiovascular Diseases Fact Sheet. World Health
Organization, September 2012. Web site:
www.who.int/mediacentre/factsheets/fs317 . 4. Women and Health Fact Sheet,
World Health Organization, November 2009. Web site:
www.who.int/mediacentre/factsheets/fs334/en/ 5. Women and Cardiovascular
Disease. World Heart Federation. Web site:
www.world-heart-federation.org/press/fact-sheets/women-and-cardiovascular-disease
.

Website: http://www.abbott.com
Contact: Media, Darcy Ross, +1-847-937-3655, or Jessica Masuga,
+1-847-935-0650, or Financial, Tina Ventura, +1-847-935-9390